Every rule in healthcare sounds certain. This episode checks what's actually holding one up. Dr. Dom on the greatest public health experiment in human history.

The Ebola outbreak in Congo passes 10,000 confirmed cases, and about 80 percent of new cases come from outside the contact lists. A modeling study prices out fewer rotavirus vaccinations, a Medicaid study links high dose opioids for back pain to later addiction, and the American Cancer Society ties living alone to higher death rates while explaining much of it away. The FDA drafts a path for personalized gene editing without new trials for each variant, and Sensible Medicine warns about subgroup rescue attempts at the coming heart meeting.

Nigeria reports its first Ebola case in a traveler from Uganda, days after the FDA cleared Uganda for blood donors. US measles cases pass 4,500 while the CDC, states and counties disagree on the death count. The FDA approves three drugs on three very different kinds of evidence, a JAMA Network Open study finds neighborhood shapes who gets diagnosed with atrial fibrillation, a preprint says only about one in nine adults with long COVID carry the code, and Sensible Medicine asks whether adult ADHD is a disease.

The CDC now wants every US-bound air passenger to swear they have not been in Congo, while the FDA and CDC disagree about whether Uganda is still an Ebola risk. A high-volume measles test was not a priority, the vaccine advisory committee will skip all of 2026, and a cancer blood test that failed its main trial endpoint may get paid for anyway. We close with a preprint predicting the shelf Ebola vaccine helps against Bundibugyo, assumptions included.

Every fall, healthy adults hear the same thing: Do it for the herd. The trials tell a narrower story. The shot protects the person who gets it, and household studies found little protection passing to anyone else.

The CDC's advisers based universal vaccination on protecting you, and in 2010 they wrote that studies of patient outcomes were "needed."

Hospitals made the shot a condition of the job anyway, and workers were fired.

In this groundbreaking episode titled " Healthcare or Wealthcare? How Monopoly Power Affects Patient Care," host Dr. Dominic Etli delves into the complex ethical landscape surrounding healthcare companies that serve dual roles. Are these corporations truly equipped to prioritize patient care, or do profit motives muddy the waters?

We scrutinize the balance of power in healthcare, examining how the dual roles of provider and payer impact patient autonomy, quality of care, and equitable access to services. With real-world examples, we explore the ethical theories and principles that should guide these corporations, from consequentialism to deontology and virtue ethics.

Join us as we navigate the ethical tightrope stretched by these healthcare giants, asking the critical questions that affect us all. Are red flags being raised? Is the quality and access to your healthcare compromised? By the end of the episode, you'll have the tools and insights to better understand how this intricate balance affects you and what it means for the future of healthcare.

Don't miss this deep dive into one of the most pressing ethical issues in modern healthcare. Whether you're a patient, healthcare provider, or simply someone interested in the ethical implications of this business model, this episode will equip you with the knowledge to navigate these murky waters.

Keywords: Dual Roles, Healthcare Ethics, Patient Autonomy, Quality of Care, Ethical Theories, Consequentialism, Deontology, Virtue Ethics, Equitable Access, Profit Motives, Healthcare Providers, Healthcare Payers, Ethical Dilemmas, Real-world Examples.

Dive deep into the world of Big Pharma with Dr. Dom on the "Ethical Consent podcast." This episode explores the controversial tactics of disease mongering and medicalization, where everyday emotions are transformed into diagnosable conditions. Discover how pharmaceutical giants strategically influence our perceptions of health and well-being. From catchy advertisements to tailored studies, uncover the deliberate strategies employed by the pharmaceutical industry. Beyond the business side, we also delve into the health ethics of such practices. Learn how genuine medical issues can be overshadowed by profit-driven agendas. Join Dr. Dom as he decodes the blurred lines between business and health, revealing Big Pharma's playbook in a world where every emotion could lead to a prescription.

In today's episode, we venture into the world of academic research to expose unsettling truths that are shaking the very foundations of trust. We focus on Francesca Gino, a once-celebrated Harvard professor, whose body of work has been called into question by vigilant scholars. But this isn't just the tale of one academic's downfall; it's a scathing indictment of a system that perpetuates dishonesty under the guise of scientific rigor.

Join me as I dissect three groundbreaking articles that cast a shadow not just on Gino's work, but on the state of academic research as a whole. As we navigate through manipulated data, suspiciously perfect p-values, and ethical quandaries, we uncover the vulnerabilities and incentives that might just be corrupting the ivory towers of academia.

If you've ever cited a study, marveled at an 'aha' finding, or held academia to a higher standard, this episode is a must-listen. It's not just about spotting the bad apples in the barrel; it's about asking if the barrel itself is rotten. Tune in and prepare to have your perspective irrevocably changed.